Healthcare
Prothena Corporation plc(PRTA)
Live Price
Offline$8.93
+5.18% today
1Y Change
+47.36%
Window
Jun 23, 2025 β Jun 18, 2026
- Market Cap
- $570.00M
- Revenue Growth
- -92.8%
- EPS Growth
- -99.6%
- Dividend Yield
- 0.0%
Coverage: 249 bars Β· Jun 23, 2025 β Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Prothena Corporation plc (PRTA) is a Healthcare stock with a market cap of $570.00M and listed on NASDAQ. The stock last traded around $8.93 and up 47.4% across the available one-year price window (Jun 23, 2025 β Jun 18, 2026). Baseline metrics include revenue growth of -92.8%, EPS growth of -99.6%, a dividend yield of 0.0%. What stands out right now is revenue -92.8%, EPS -99.6%, free cash flow -8.9% with operating margin -2247.5% and ROIC -75.4%. Valuation already assumes a fairly strong business story at price/sales 59.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PRTA price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-92.8% vs +7.6% peer median
Operating Margin
Below sector median
-2247.5% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 14, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -92.8% and EPS is at -99.6%, with operating margin around -2247.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.6% over the next 5 trading days and finished higher after 1 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS Ξ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 14, 2026 | β | -1.0% | -4.6% | -16.3% |
2026 Feb 19, 2026 | +2.2% | -0.1% | -4.3% | -5.4% |
2025 Nov 6, 2025 | -11.7% | +4.8% | +1.0% | +9.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PRTA
β
Normalized return
SPY
β
S&P 500
Excess Return
β
Relative to SPY
PRTA Max Drawdown
-31.28%
Trailing 1Y
SPY Max Drawdown
β
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PRTA and SPY.
Company Overview
Prothena Corporation plc
NASDAQ Global Select
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual AΓ-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
- Leadership
- Gene G. Kinney
- IPO Date
- Dec 18, 2012
- Employees
- 163
- Street Address
- 77 Sir John Rogersonβs Quay
- Mailing
- Dublin, 2
- Region
- Dublin, IE
- Reporting Currency
- USD
- Investor Line
- 353 1 236 2500
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- β
- EV/EBITDA
- β
- Price/Sales
- 59.1
- Price/Book
- 2.0
Growth
- Revenue
- -92.8%
- EPS
- -99.6%
- Free Cash Flow
- -8.9%
Profitability
- Gross Margin
- -208.6%
- Operating Margin
- -2247.5%
- Net Margin
- -2520.6%
- ROE
- -73.0%
- ROIC
- -75.4%
Balance Sheet
- Debt/Equity
- 0.05
- Current Ratio
- 7.72
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.